Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 9/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19276640 | 0.89 | ADORA3 (0.37) | ADORA3CAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL27325818 | 0.82 | CA1 (0.35) | ADORA3CA1CA2CA9 | |
| SCHEMBL12110848 | 0.82 | ADORA3 (0.43) | ADORA3CAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL18971275 | 0.80 | ADORA2A (0.40) | ADORA3MAPK1CA1CA2CA9 | |
| SCHEMBL18971276 | 0.80 | ADORA2A (0.40) | ADORA3MAPK1CA1CA2CA9 | |
| SCHEMBL18971706 | 0.80 | ADORA2A (0.40) | ADORA3MAPK1CA1CA2CA9 | |
| SCHEMBL5763778 | 0.79 | ADORA2A (0.41) | ADORA3MAPK1 | |
| SCHEMBL4380400 | 0.79 | ADORA2A (0.41) | ADORA3MAPK1 | |
| SCHEMBL5742266 | 0.79 | ADORA2A (0.41) | ADORA3MAPK1 | |
| SCHEMBL5413280 | 0.79 | ADORA2A (0.41) | ADORA3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030360-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | US ARMY, SECRETARY OF THE ARMY | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030360-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | ADORA3 2630/4885CAPN1 1688/4885CTSB 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.